Idiopathic pulmonary fibrosis: Misunderstandings between epithelial cells and fibroblasts?

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 21, Issue 3, 2004, Pages 165-172

  Selman, Moisés ^a   Pardo, Annie ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Epithelial cells; Fibroblasts; Lung fibrosis; Myofibroblasts; Stem cells

Indexed keywords

APOPTOSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; LUNG ALVEOLITIS; LUNG ALVEOLUS CELL; LUNG FIBROSIS; MEMBRANE DAMAGE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW;

APOPTOSIS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; PULMONARY FIBROSIS;

EID: 8144226794     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-64.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
3. Crystal RG, Bitterman PB, Mossman B, et al: Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002; 166: 236-46.
4. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis; prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
5. Pardo A, Selman M: Molecular mechanisms of pulmonary fibrosis. Frontiers in Bioscience 2002; 7, 1743-61, August 1.
6. Pardo A, Selman M: Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol 2002; 34: 1534-8.
7. Selman M, Pardo A: The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Tying loose ends. Am J Respir Cell Molec Biol 2003; 29 (Suppl.): S93-S97.
8. Travis DWD: Non-neoplastic disorders of the lower respiratory tract. In: Travis DWD, Colby TV, Koss MN, Rosado de Chritenson ML, Muller NL, King TE (eds): The American Registry of Pathology. Atlas of Nontumor Pathology, First Series, Fascicle 2, 2002.
9. Qunn L, Takemura T, Ikushima S, et al: Hyperplastic epithelial foci in honeycomb lesions in idiopathic pulmonary fibrosis. Virchows Arch 2002; 441: 271-8.
10. Honda T, Ota H, Arai K, et al: Three-dimensional analysis of alveolar structure in usual interstitial pneumonia. Virchows Arch 2002; 441: 47-52.
11. Marchand-Adam S, Marchal J, Cohen M, et al: Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 1156-61.
12. Sakai T, Satoh K, Matsushima K, et al: Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization. Am J Respir Cell Mol Biol 1997; 16: 388-97.
13. Crestani B, Dehoux M, Hayem G, et al: Differential role of neutrophils and alveolar macrophages in hepatocyte growth factor production in pulmonary fibrosis. Lab Invest 2002; 82: 1015-22.
14. Mori M, Morishita H, Nakamura H, et al: Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth. Am J Respir Cell Mol Biol 2004; 30: 459-09.
15. Mori M, Kida H, Morishita H, et al: Microsatellite instability in transforming growth factor-β 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2001; 24: 398-404.
16. Zuo F, Kaminski N, Eugui E, et al: Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-7.
17. Selman M, Ruiz V, Cabrera S, et al: TIMP-1, -2, -3 and -4 in idiopathic pulmonary fibrosis. A prevailing non degradative lung microenvironment? Am J Physiol 2000; 279: L562-74.
18. Lappi-Blanco E, Kaarteenaho-Wiik R, Salo S, et al: Laminin-5 gamma2 chain in cryptogenic organizing pneumonia and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 27-33.
19. Kuwano K, Kunitake R, Kawasaki M, et al: P21 Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154: 477-83.
20. Uhal BD, Joshi I, Hughes CWF, Ramos C, Pardo A, Setman M: Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998; 275: L1192-9.
21. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL: Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 2001; 54: 132-8.
22. Maeyama T, Kuwano K, Kawasaki M, et al: Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17: 180-9.
23. Wang R, Ramos C, Joshi I, et al: Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol 1999; 277: L1158-64.
24. Kuwano K, Nakashima N, Inoshima I, et al: Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003; 21: 232-40.
25. Antoniades HN, Bravo M, Avila R, Galanopoulus T, Neville J, Selman M: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055-64.
26. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G: Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995; 152: 2163-9.
27. Nash JR, McLaughlin PJ, Butcher D, Corrin B: Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology 1993; 22: 343-7.
28. Khalil N, O'Connor RN, Unruh HW, et al: Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5: 155-62.
29. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q: Expression of endothelin-1 in lung of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-4.
30. Pan LH, Yamauchi K, Uzuki M, et al: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001; 17: 1220-7.
31. Ebina M, Shimizukawa M, Shibata N, et al: Heterogeneous increase in CD34-positive alveolar capillaries in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-8.
32. Cosgrove GP, Brown KK, Schiemann WP, et al: Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004, in press.
33. Chambers RC, Laurent GJ: Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans 2002; 30: 194-200.
34. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A: Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
35. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A: Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-6.
36. Fujii M, Hayakawa H, Urano T, et al: Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99: 111-7.
37. Murphy G, Stanton H, Cowell S, et al: Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44.
38. Legrand C, Polette M, Tournier JM, et al: uPa/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264: 326-36.
39. Howell DC, Laurent GJ, Chambers RC: Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans 2002; 30: 211-6.
40. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A: Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-92.
41. Pan T, Mason RJ, Westcott JY, Shannon JM: Rat alveolar type II cells inhibit lung fibroblast proliferation in vitro. Am J Respir Cell Mol Biol 2001; 25: 353-61.
42. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 2002; 27: 752-8.
43. Kohyama T, Ertl R, Valenti V, et al: Prostaglandin E2 inhibits fibroblast chemotaxis. Am J Physiol 2001; 281: L1257-63.
44. Petkova DK, Clelland CA, Ronan JE, Lewis S, Knox AJ: Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003; 43: 381-6.
45. Xaubet A, Roca-Ferrer J, Pujols L, et al: Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 35-42.
46. Dai J, Gilks B, Price K, Churg A: Mineral dusts directly induce epithelial and interstitial fibrogenic mediators and matrix components in the airway wall. Am J Respir Crit Care Med 1998; 158: 1907-13.
47. Xu YD, Hua J, Mui A, O'Connor R, Grotendorst G, Khalil N: Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis. Am J Physiol 2003; 285: L527-39.
48. Hardie WD, Le Cras TD, Jiang K, Tichelaar JW, Azhar M, Korfhagen TR: Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am J Physiol 2004; 286: L741-9.
49. Korbet SM: Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23: 219-28.
50. Franceschini N, Hogan SL, Falk RJ: Primum non nocere: Should adults with idiopathic FSGS receive steroids? Semin Nephrol 2003; 23: 229-33.
51. Barisoni L, Mundel P: Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol 2003; 23: 353-60.
52. Schwartz MM: The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren Fail 2000; 22: 663-84.
53. Yang GP, Lim IJ, Phan TT, Lorenz HP, Longaker MT: From scarless fetal wounds to keloids: molecular studies in wound healing. Wound Repair Regen 2003; 11: 411-18.
54. Funayama E, Chodon T, Oyama A, Sugihara T: Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid. J Invest Dermatol 2003; 121: 1326-31.
55. Lim IJ, Phan TT, Bay BH, et al: Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloidlike manner. Am J Physiol 2002; 283: C212-22.
56. Heike T, Nakahata T: Stem cell plasticity in the hematopoietic system. Int J Hematol 2004; 79: 7-14.
57. Epperly MW, Guo H, Gretton JE, Greenberger JS: Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29: 213-24.
58. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH; Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113: 243-52.
59. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN: Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-62.
60. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R: Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.
61. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S: Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171: 380-9.
62. Phillips RJ, Murray LA, Burdick MD, et al: Circulating CD45+, Coll+, CXCR4+ progenitor fibrocytes traffic to the lung in response to CXCL12, and mediate pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: A24.
63. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
64. Iwano M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 279-84.
65. Chilosi M, Poletti V, Zamo A. et al: Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162: 1495-502.
66. Lappi-Blanco E, Soini Y, Paakko P: Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999; 177: 367-76.
67. Moodley YP, Caterina P, Scaffidi AK, et al: Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis. J Pathol 2004; 202: 486-95.
68. Moodley YP, Misso NL, Scaffidi AK, et al: Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 2003; 29: 490-8.
69. Lappi-Blanco E, Kaarteenaho-Wiik R, Soini Y, Risteli J, Paakko P: Intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia are highly capillarized. Hum Pathol 1999; 30: 1192-6.
70. Fukuda Y, Ishizaki M, Kudoh S, Kitaichi M, Yamanaka N: Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 1998; 78: 687-98.
71. Hayashi T, Stetler-Stevenson WG, Fleming MV, et al: Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996; 149: 1241-56.